ANNX Stock Analysis: Annexon | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 977m USD | 12M Return: 135.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.2M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Annexon, Inc. (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Brisbane, California, that develops therapies for inflammatory-related diseases. Its pipeline is anchored by Tanruprubart, an investigational monoclonal antibody in Phase 3 for Guillain-Barré syndrome, with additional completed Phase II work in Huntingtons disease and Phase 2a testing in amyotrophic lateral sclerosis (ALS). The company is also advancing ANX007, an antigen-binding fragment (Fab) in Phase 3 development for geographic atrophy, as well as earlier-stage candidates ANX1502 (an oral small molecule inhibitor for autoimmune indications) and ANX009 (a C1q-blocking Fab for lupus nephritis).
Annexon operates as a clinical-stage biotech, meaning it has no marketed products and is dependent on capital markets and partnerships to fund its R&D. The companys pipeline centers on modulating the classical complement pathway, an arm of the immune system implicated in autoimmune and neurodegenerative conditions, which distinguishes its scientific approach within the broader immunology and ophthalmology drug development space.
- Tanruprubart Phase 3 Guillain-Barré syndrome readout approaches
- ANX007 geographic atrophy Phase 3 faces Syfovre and Izervay competition
- Cash burn and small cap status raise dilution risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.70 > 0.02 and ΔFCF/TA -23.51 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.70 > 3% & CFO -183.1m > Net Income -196.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (194.2m) vs 12m ago 31.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.12%; Δ -1.12% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 228.3m - Total Current Liabilities 35.9m) / Total Assets 262.9m |
| B: -3.66 (Retained Earnings -961.5m / Total Assets 262.9m) |
| C: -0.69 (EBIT TTM -196.5m / Avg Total Assets 283.0m) |
| D: 3.50 (Book Value of Equity 204.5m / Total Liabilities 58.4m) |
| Altman-Z'' = -8.11 = D |
As of July 08, 2026, the stock is trading at USD 6.43 with a total of 5,753,669 shares traded. Over the past week, the price has changed by +15.44%, over one month by +25.59%, over three months by +7.35% and over the past year by +135.53%.
Current recommended Stop Loss: 5.40 (which is 16% or 2.7 ATR below the current price).
Annexon has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ANNX.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.1 | 104.2% |
P/B = 4.3738
Revenue TTM = 0.0 USD
EBIT TTM = -196.5m USD
EBITDA TTM = -193.4m USD
Long Term Debt = 22.4m USD (estimated: total debt 25.4m - short term 3.02m)
Short Term Debt = 3.02m USD (from shortTermDebt, last quarter)
Debt = 25.4m USD (from shortLongTermDebtTotal, last quarter) (leases 25.4m already included)
Net Debt = -199.6m USD (calculated: Debt 25.4m - CCE 225.0m)
Enterprise Value = 776.9m USD (976.5m + Debt 25.4m - CCE 225.0m)
Interest Coverage Ratio = unknown (Ebit TTM -196.5m / Interest Expense TTM 0.0)
EV/FCF = -4.24x (Enterprise Value 776.9m / FCF TTM -183.2m)
FCF Yield = -23.58% (FCF TTM -183.2m / Enterprise Value 776.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.69m) / Revenue TTM)
Tobins Q-Ratio = 2.96 (Enterprise Value 776.9m / Total Assets 262.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 25.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -155.2m (EBIT -196.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.35 (Total Current Assets 228.3m / Total Current Liabilities 35.9m)
Debt / Equity = 0.12 (Debt 25.4m / totalStockholderEquity, last quarter 204.5m)
Debt / EBITDA = 1.03 (negative EBITDA) (Net Debt -199.6m / EBITDA -193.4m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -199.6m / FCF TTM -183.2m)
Total Stockholder Equity = 194.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.44% (Net Income -196.5m / Total Assets 262.9m)
RoE = -101.2% (Net Income TTM -196.5m / Total Stockholder Equity 194.2m)
RoCE = -90.72% (EBIT -196.5m / Capital Employed (Equity 194.2m + L.T.Debt 22.4m))
RoIC = -67.49% (negative operating profit) (NOPAT -155.2m / Invested Capital 230.0m)
WACC = 10.44% (E(976.5m)/V(1.00b) * Re(10.71%) + D(25.4m)/V(1.00b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 49.81%
[DCF] Fair Price = unknown (Cash Flow -183.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.07 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.24 | Chg30d=+20.57% | Revisions=+57% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.25 | Chg30d=+11.11% | Revisions=+57% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.98 | Chg30d=+15.53% | Revisions=+57% | GrowthEPS=+26.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.92 | Chg30d=+3.46% | Revisions=+29% | GrowthEPS=+6.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +74% (up=15, down=1)